Showing results (1701-1710 of 1,800) with videos related to
Sort By:
Pageof 180
Antibiotics (Basel, Switzerland)|February 25, 2023
Multicenter Surveillance of Antimicrobial Resistance among Gram-Negative Bacteria Isolated from Bloodstream Infections in GhanaEric S Donkor, Khitam Muhsen, Sherry A M Johnson, et al.Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.Intensive Care Medicine|September 14, 2022
Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trialM Fish, J Rynne, A Jennings, et al.Journal of Viral Hepatitis|August 29, 2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registryZobair M Younossi, Ming-Lung Yu, Mohamed El-Kassas, et al.JAMA|March 21, 2023
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19Ewan C Goligher, Patrick R Lawler, Thomas P Jensen, et al.Blood|October 1, 1995
Bone marrow transplantation for Fanconi anemiaE Gluckman, A D Auerbach, M M Horowitz, et al.Frontiers in Immunology|April 16, 2014
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosisCarlo Selmi, Francesca Cavaciocchi, Ana Lleo, et al.Journal of Clinical Microbiology|May 5, 2017
Whole-Genome Sequencing Reveals the Contribution of Long-Term Carriers in Staphylococcus aureus Outbreak InvestigationN C Gordon, B Pichon, T Golubchik, et al.Lancet (London, England)|August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stanislas Pol, Ira M Jacobson, et al.Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 TrialEdward J Gane, Kris V Kowdley, David Pound, et al.Pageof 180